The Danish Life Science Council says the EU must be better at prevention, embracing personalised medicine and emerging ...

"We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include ...

When I was penning my latest column for Pharma Commerce, I felt that various recent developments were worth noting, ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 5.51%, which has investors questioning if this is right time to buy.

AscellaHealth has announced its role as a Silver Sponsor of the World Orphan Drug Congress USA (WODC), which will convene ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

From albums to musicals, as well as live broadcasts and video game soundtracks, the Library of Congress has unveiled this ...

Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel ...

NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its ...

The Company anticipates filing its NDA for GTx-104 in the second quarter of 2025. Acceptance of the NDA will be subject to the FDA’s review of the complete filing.

With its gritty themes and unforgettable storylines, Byker Grove was one of the most iconic shows of the 90s and 00s. Here ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.